These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 1547574)

  • 21. Monitoring Intravenous Abuse of Methadone or Buprenorphine in Opiate Maintenance Treatment (OMT): A Simple and Fast LC-MS-MS Method for the Detection of Disaccharides in Urine Samples.
    Jungen H; Andresen-Streichert H; Müller A; Iwersen-Bergmann S
    J Anal Toxicol; 2017 Jan; 41(1):22-31. PubMed ID: 28130543
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of drugs of abuse in exhaled breath from users following recovery from intoxication.
    Beck O; Stephanson N; Sandqvist S; Franck J
    J Anal Toxicol; 2012; 36(9):638-46. PubMed ID: 23045289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lower Cutoffs for LC-MS/MS Urine Drug Testing Indicates Better Patient Compliance.
    Krock K; Pesce A; Ritz D; Thomas R; Cua A; Rogers R; Lipnick P; Kilbourn K
    Pain Physician; 2017 Nov; 20(7):E1107-E1113. PubMed ID: 29149155
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of tramadol use on three point-of-care and one instrument-based immunoassays for urine buprenorphine.
    Shaikh S; Hull MJ; Bishop KA; Griggs DA; Long WH; Nixon AL; Flood JG
    J Anal Toxicol; 2008 Jun; 32(5):339-43. PubMed ID: 18544218
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new highly specific buprenorphine immunoassay for monitoring buprenorphine compliance and abuse.
    Melanson SE; Snyder ML; Jarolim P; Flood JG
    J Anal Toxicol; 2012 Apr; 36(3):201-6. PubMed ID: 22417836
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of glutaraldehyde (UrinAid) on detection of abused drugs in urine by immunoassay.
    Goldberger BA; Caplan YH
    Clin Chem; 1994 Aug; 40(8):1605-6. PubMed ID: 8045013
    [No Abstract]   [Full Text] [Related]  

  • 27. Laboratory and clinical evaluation of on-site urine drug testing.
    Beck O; Carlsson S; Tusic M; Olsson R; Franzen L; Hulten P
    Scand J Clin Lab Invest; 2014 Nov; 74(8):681-6. PubMed ID: 25046332
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reducing false-negative tests in urinary drugs-of-abuse screening.
    Luceri F; Godi F; Messeri G
    J Anal Toxicol; 1997; 21(3):244-5. PubMed ID: 9171214
    [No Abstract]   [Full Text] [Related]  

  • 29. [Creatinine concentration in urine should be measured in drug testing. Guidelines for decision limits and interpretation are necessary--at any rate for legal rights].
    Helander A; Ohlson M; Beck O; Hansson T; Kugelberg FC; Kronstrand R
    Lakartidningen; 2011 Jun 15-28; 108(24-25):1311-4. PubMed ID: 21830503
    [No Abstract]   [Full Text] [Related]  

  • 30. Validation of the Immunalysis microplate ELISA for the detection of buprenorphine and its metabolite norbuprenorphine in urine.
    Miller EI; Torrance HJ; Oliver JS
    J Anal Toxicol; 2006 Mar; 30(2):115-9. PubMed ID: 16620543
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical issues associated with urine testing of substances of abuse.
    Eskridge KD; Guthrie SK
    Pharmacotherapy; 1997; 17(3):497-510. PubMed ID: 9165553
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Screening for drugs of abuse (II): Cannabinoids, lysergic acid diethylamide, buprenorphine, methadone, barbiturates, benzodiazepines and other drugs.
    Simpson D; Braithwaite RA; Jarvie DR; Stewart MJ; Walker S; Watson IW; Widdop B
    Ann Clin Biochem; 1997 Sep; 34 ( Pt 5)():460-510. PubMed ID: 9293303
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantitative testing of buprenorphine and norbuprenorphine to identify urine sample spiking during office-based opioid treatment.
    Suzuki J; Zinser J; Issa M; Rodriguez C
    Subst Abus; 2017; 38(4):504-507. PubMed ID: 28723256
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Buprenorphine detection in urine using liquid chromatography-high-resolution mass spectrometry: comparison with cloned enzyme donor immunoassay (ThermoFisher) and homogeneous enzyme immunoassay (immunalysis).
    Belsey SL; Couchman L; Flanagan RJ
    J Anal Toxicol; 2014 Sep; 38(7):438-43. PubMed ID: 24925983
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The development and application of a rapid gas chromatography-mass spectrometry method to monitor buprenorphine withdrawal protocols.
    George S; George C; Chauhan M
    Forensic Sci Int; 2004 Jul; 143(2-3):121-5. PubMed ID: 15240031
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapid quantification of buprenorphine-glucuronide and norbuprenorphine-glucuronide in human urine by LC-MS-MS.
    Hegstad S; Khiabani HZ; Øiestad EL; Berg T; Christophersen AS
    J Anal Toxicol; 2007 May; 31(4):214-9. PubMed ID: 17555645
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of intect test strips for detecting adulteration of urine specimens used for drugs-of-abuse testing.
    King EJ
    J Anal Toxicol; 2000 Sep; 24(6):456. PubMed ID: 10999355
    [No Abstract]   [Full Text] [Related]  

  • 38. Interpretation of urine drug testing results in patients using transdermal buprenorphine preparations for the treatment of chronic noncancer pain.
    Markman JD; Barbosa WA; Gewandter JS; Frazer M; Rast S; Dugan M; Nandigam K; Villareal A; Kwong TC
    Pain Med; 2015 Jun; 16(6):1132-6. PubMed ID: 25800409
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Performance of AdultaCheck 4 test strips for the detection of adulteration at the point of collection of urine specimens used for drugs-of-abuse testing.
    King EJ
    J Anal Toxicol; 1999; 23(1):72. PubMed ID: 10022215
    [No Abstract]   [Full Text] [Related]  

  • 40. Urinalysis-based comparative evaluation of pattern of use of dextropropoxyphene and buprenorphine among opioid-dependent subjects.
    Balhara YP; Jain R
    J Opioid Manag; 2012; 8(1):45-9. PubMed ID: 22479884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.